Nuvig Therapeutics halts Phase 2 trial of NVG-2089 in chronic inflammatory demyelinating polyneuropathy
Nuvig Therapeutics announced it is terminating one of its two ongoing clinical programs, a Phase 2 study of its candidate NVG-2089.
The trial was designed to evaluate NVG-2089 in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune nerve disorder.
The company said the decision reflects a strategic reassessment of its pipeline, and it will continue to pursue other programs, including its remaining trial.
The brief also noted other industry updates, mentioning activities at RevMed, Tang Capital, GSK and AmyriAD Therapeutics, though details were not provided.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Nuvig drops a Phase 2 trial; Cerevance reports Parkinson's progress”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that